The Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE) randomized controlled trial included 3,073 eligible patients between 2020-2023. The trial examined whether chatbot and standard of care approaches are equivalent in completion of pre-test cancer genetic services and genetic testing.
